Can-Fite BioPharma annual capital expenditures (capex)
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Capital Expenditures (CapEx) Growth & History (CANF)
Can-Fite BioPharma's capital expenditures (capex) was $2,000 for fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2,000 | −$3,000 | −60.00% |
| 2024 | 2024-12-31 | $5,000 | $3,000 | +150.00% |
| 2023 | 2023-12-31 | $2,000 | −$7,000 | −77.78% |
| 2022 | 2022-12-31 | $9,000 | −$2,000 | −18.18% |
| 2021 | 2021-12-31 | $11,000 | −$15,000 | −57.69% |
| 2020 | 2020-12-31 | $26,000 | $23,000 | +766.67% |
| 2019 | 2019-12-31 | $3,000 | −$30,000 | −90.91% |
| 2018 | 2018-12-31 | $33,000 | $26,000 | +371.43% |
| 2017 | 2017-12-31 | $7,000 | −$3,000 | −30.00% |
| 2016 | 2016-12-31 | $10,000 | — | — |
Can-Fite BioPharma capital expenditures (capex) trends
Over the last five fiscal years, Can-Fite BioPharma's capital expenditures (capex) decreased from $26,000 to $2,000, a change of −$24,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma source filings ↗